Naeblys/iStock via Getty Images Prime Medicine ( NASDAQ: PRME ) and Bristol Myers Squibb ( NYSE: BMY ) will work together on the development of next-generation ex vivo T-cell therapies. The deal calls for Prime Medicine to design optimized Prime Editor reagents for several targets. Bristol Myers Squibb will handle development, manufacturing and commercialization of.
